Akorn Pharmaceuticals, a medical device maker that specializes in cardiac stimulators, was one of the first companies to announce a drug that could treat patients with ventricular fibrillation.
Akhorn has now raised a $6 billion round led by Google Ventures.
It also raised another $1 billion in Series B funding.
The company’s CEO, Peter Akorn, said in a blog post that he expects the drug to have a “positive impact on the lives of patients in need of a drug to help control their ventricular arrhythmias.”
A study published in the New England Journal of Medicine found that Akorn’s drug would lower ventricular BP by 10 percent and lower the rate of heart failure by 25 percent.
Its announcement comes after Akorn raised $4.5 billion in a Series B in January, but the company said that it’s currently undercapitalized and has no plans to raise any additional funds.
The company announced the drug, which is known as Akorn CX-2, at its annual meeting on Tuesday.
The company says that the drug would reduce the rate at which patients experience cardiac arrest by 20 percent.
The drug will be developed by a team of researchers at the University of Michigan and the University at Buffalo, according to a statement from the company.
Akorn says the drug will treat patients whose BP has exceeded 180/80.
Akorn is developing the drug in partnership with Roche, a pharmaceutical company that also develops cardiac stimulants.
It’s unclear if Akorn plans to pursue a Phase III trial for the drug.
The New England study, which looked at patients with at least two major ventricular events, found that patients treated with Akorn had a reduction in BP of 20 percent to 35 percent, compared with patients treated without the drug and those who received a placebo.
The study found that people treated with the drug had a lower risk of developing heart failure than those treated with placebo.
Akorn said in its announcement that the company is planning to commercialize the drug as early as next year.